AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9079579 — intervention group
Group type: EXPERIMENTAL
Intervention: multicomponent smoking cessation intervention (printed guide, video, telephone booster call)
Number of subjects: 0
Study 9079579 — intervention group
Group type: COMPARATOR
Intervention: health education materials not directly addressing tobacco use
Number of subjects: 0
Study 8399091 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil-enriched diet
Number of subjects: 15
Study 8399091 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil-enriched diet
Number of subjects: 15
Study 8399091 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-enriched diet
Number of subjects: 15
Study 8399091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable oil-enriched diets
Number of subjects: 15
Study 8399091 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 15
Study 3945535 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg
Number of subjects: 12
Study 3945535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31504303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of sofosbuvir (400 mg) and daclatasvir (60 mg)
Number of subjects: 1361
Study 31504303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of sofosbuvir and daclatasvir with or without ribavirin
Number of subjects: 1361
Study 29528504 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraising the emotion-eliciting stimulus
Number of subjects: 90
Study 29528504 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraising their emotional response
Number of subjects: 90
Study 29528504 — intervention group
Group type: COMPARATOR
Intervention: No specific emotion regulation instructions (Control)
Number of subjects: 90
Study 26920816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar temporary ventricular epicardial pacing leads
Number of subjects: 50
Study 26920816 — intervention group
Group type: COMPARATOR
Intervention: Unipolar temporary ventricular epicardial pacing leads
Number of subjects: 50
Study 25033291 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 61
Study 25033291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (25 mg/kg) + Praziquantel (40 mg/kg)
Number of subjects: 61
Study 25033291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (3× (100 mg artesunate + 250 mg mefloquine)) + Praziquantel (40 mg/kg)
Number of subjects: 61
Study 23032322 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+HEX (Hextend 6% hetastarch in lactated electrolyte buffer)
Number of subjects: 281
Study 23032322 — intervention group
Group type: COMPARATOR
Intervention: SOC (crystalloid plus blood products)
Number of subjects: 281
Study 23032322 — intervention group
Group type: EXPERIMENTAL
Intervention: HEX (in ER and OR)
Number of subjects: 281
Study 20308616 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus bromocriptine for 8 weeks (PPCM-Br)
Number of subjects: 20
Study 20308616 — intervention group
Group type: COMPARATOR
Intervention: Standard care (PPCM-Std)
Number of subjects: 20
Study 20308616 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus bromocriptine (PPCM-Br)
Number of subjects: 20
Study 18490845 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo (two capsules containing powdered ginseng 250 mg, powdered oriental bezoar 50 mg, and powdered glycyrrhiza 50 mg)
Number of subjects: 10
Study 18490845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch)
Number of subjects: 10
Study 18490845 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo
Number of subjects: 10
Study 15727498 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg/70 kg
Number of subjects: 8
Study 15727498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.75 mg/70 kg
Number of subjects: 8
Study 15727498 — intervention group
Group type: COMPARATOR
Intervention: Saline iv
Number of subjects: 8
Study 15727498 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug reinforcement opportunity (fentanyl 1.5 mg/70 kg iv)
Number of subjects: 8
Study 15727498 — intervention group
Group type: COMPARATOR
Intervention: Money reinforcement opportunity
Number of subjects: 8
Study 12601441 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0
Study 12601441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10599652 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 fractions of 2 Gy external beam irradiation (n = 101)
Number of subjects: 205
Study 10599652 — intervention group
Group type: COMPARATOR
Intervention: 8 fractions of 0 Gy (sham treatment, n = 104)
Number of subjects: 205
Study 10599652 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 fractions of 2 Gy external beam irradiation
Number of subjects: 205
Study 10599652 — intervention group
Group type: COMPARATOR
Intervention: 8 fractions of 0 Gy (sham treatment)
Number of subjects: 205
Study 10599652 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity in the presence of classic CNV (treatment group)
Number of subjects: 205
Study 10599652 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity in the presence of classic CNV (control group)
Number of subjects: 205
Study 10599652 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity in patients with occult CNV (treatment group)
Number of subjects: 205
Study 10599652 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity in patients with occult CNV (control group)
Number of subjects: 205
Study 7854516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level vagus nerve stimulation (presumed therapeutic dose)
Number of subjects: 114
Study 7854516 — intervention group
Group type: COMPARATOR
Intervention: Low-level vagus nerve stimulation (presumed subtherapeutic dose)
Number of subjects: 114
Study 7854516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level vagus nerve stimulation
Number of subjects: 114
Study 7854516 — intervention group
Group type: COMPARATOR
Intervention: Low-level vagus nerve stimulation
Number of subjects: 114
Study 2048560 — intervention group
Group type: COMPARATOR
Intervention: rhGM-CSF
Number of subjects: 81
Study 2048560 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 81
Study 7015799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release quinidine 0.4 g twice a day
Number of subjects: 53
Study 7015799 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 80 mg three times a day
Number of subjects: 53
Study 31073884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish (300 g/week)
Number of subjects: 199
Study 31073884 — intervention group
Group type: COMPARATOR
Intervention: Poultry (control)
Number of subjects: 199
Study 29338563 — intervention group
Group type: EXPERIMENTAL
Intervention: New Perspectives (NP)
Number of subjects: 101
Study 29338563 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 101
Study 27128545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 0
Study 27128545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24452701 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal digital assistant training and support for eight weeks by an occupational therapist
Number of subjects: 42
Study 24452701 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation including use of non‐electronic memory aids
Number of subjects: 42
Study 22192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad flap (PBFPF)
Number of subjects: 22
Study 22192386 — intervention group
Group type: COMPARATOR
Intervention: Classic buccal sliding flap
Number of subjects: 22
Study 20147875 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program
Number of subjects: 348
Study 20147875 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + Physiotherapy program
Number of subjects: 348
Study 20147875 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 348
Study 17935517 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(-1) ointment
Number of subjects: 50
Study 17935517 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.3 mg g(-1) ointment
Number of subjects: 50
Study 16295337 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised learning
Number of subjects: 50
Study 16295337 — intervention group
Group type: COMPARATOR
Intervention: Integrative learning
Number of subjects: 50
Study 16295337 — intervention group
Group type: COMPARATOR
Intervention: Combination of integrative and computerised learning
Number of subjects: 50
Study 11927525 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR) < 2.5 after angioplasty
Number of subjects: 379
Study 11927525 — intervention group
Group type: EXPERIMENTAL
Intervention: CFVR before PTCA
Number of subjects: 379
Study 11927525 — intervention group
Group type: EXPERIMENTAL
Intervention: CFVR in reference artery
Number of subjects: 379
Study 11927525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFVR at the end of the procedure
Number of subjects: 379
Study 11927525 — intervention group
Group type: COMPARATOR
Intervention: Patients with CFVR < 2.5 at the end of the procedure
Number of subjects: 379
Study 9563887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 450 mg/m2 i.v. for 5 days followed by 15 mg/kg i.v. weekly (arm 1)
Number of subjects: 199
Study 9563887 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus levamisole 50 mg p.o. every 8 h for 3 days every 2 weeks (arm 2)
Number of subjects: 199
Study 7665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Poly diet (n = 22)
Number of subjects: 67
Study 7665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Mono diet (n = 20)
Number of subjects: 67
Study 7665996 — intervention group
Group type: COMPARATOR
Intervention: Human Milk diet (n = 25)
Number of subjects: 67
Study 7665996 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Hi-Mono, Hi-Poly, Human Milk)
Number of subjects: 67
Study 2510604 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + UFT (A)
Number of subjects: 29
Study 2510604 — intervention group
Group type: COMPARATOR
Intervention: MMC + tegafur (B)
Number of subjects: 29
Study 31005927 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time colonoscopy (n=4000)
Number of subjects: 20000
Study 31005927 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual faecal immunochemical test (FIT) (n=8000)
Number of subjects: 20000
Study 31005927 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual risk-adapted screening strategy (n=8000)
Number of subjects: 20000
Study 28002447 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg/mL)
Number of subjects: 60
Study 28002447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 60
Study 25112970 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 9
Study 25112970 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 9
Study 21659897 — intervention group
Group type: EXPERIMENTAL
Intervention: High habitual physical activity (>500-1200 MET · min · wk(‐1))
Number of subjects: 58610
Study 21659897 — intervention group
Group type: COMPARATOR
Intervention: Low habitual physical activity (≤ 100 MET · min · wk(‐1))
Number of subjects: 58610
Study 21659897 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity
Number of subjects: 58610
Study 21659897 — intervention group
Group type: EXPERIMENTAL
Intervention: High habitual physical activity
Number of subjects: 58610
Study 20044242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 100 microg
Number of subjects: 17
Study 20044242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 300 microg
Number of subjects: 17
Study 20044242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 900 microg
Number of subjects: 17
Study 20044242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18781665 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance interpersonal psychotherapy (IPT-M)
Number of subjects: 131
Study 16374685 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation at a dosage of 3.1 ± 0.6 mg/kg/day for 9 months
Number of subjects: 15
Study 16374685 — intervention group
Group type: COMPARATOR
Intervention: Conventional antifailure drugs
Number of subjects: 15
Study 12357147 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg OROS formulation
Number of subjects: 12
Study 12357147 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg IR formulation
Number of subjects: 12
Study 12357147 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS formulation
Number of subjects: 12
Study 9187165 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline at the established optimal dose (range, 300 to 700 mg) plus inhaled placebo
Number of subjects: 19
Study 9187165 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo plus inhaled (40 microg) ipratropium
Number of subjects: 19
Study 9187165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of theophylline and ipratropium
Number of subjects: 19
Study 9187165 — intervention group
Group type: COMPARATOR
Intervention: Oral and inhaled placebo
Number of subjects: 19
Study 2007362 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg daily (N = 25)
Number of subjects: 49
Study 2007362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 24)
Number of subjects: 49
Study 7124726 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.05% NaCl (osmotic activity equivalent to 15 ml of 23.5% NaCl)
Number of subjects: 20
Study 7124726 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dextrose
Number of subjects: 20
Study 7124726 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 20
Study 31473000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine based on the attenuated AlHV‐1 C500 strain, administered as prime and boost inoculations one month apart.
Number of subjects: 146
Study 31473000 — intervention group
Group type: COMPARATOR
Intervention: Culture medium mixed with Emulsigen® (control group).
Number of subjects: 146
Study 27898183 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg twice daily (EXE)
Number of subjects: 30
Study 27898183 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 30
Study 25327775 — intervention group
Group type: EXPERIMENTAL
Intervention: Office evaluation plus urodynamic studies (UDS)
Number of subjects: 630
Study 25327775 — intervention group
Group type: COMPARATOR
Intervention: Office evaluation (OE)
Number of subjects: 630
Study 25099425 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy curriculum
Number of subjects: 1170
Study 22227168 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 200
Study 22227168 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (control)
Number of subjects: 200
Study 19508989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 40
Study 19508989 — intervention group
Group type: COMPARATOR
Intervention: Expectantly managed fetuses with CDH of variable severity
Number of subjects: 40
Study 17921706 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery (BCS) plus radiation therapy (RT)
Number of subjects: 0
Study 17921706 — intervention group
Group type: COMPARATOR
Intervention: Breast conserving surgery (BCS) alone
Number of subjects: 0
Study 15067339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5-FU) for 1 year in patients receiving surgery and radiotherapy (SR)
Number of subjects: 1542
Study 15067339 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 1542
Study 15067339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5-FU) for 1 year in patients with pelvic lymph node metastases
Number of subjects: 1542
Study 11340355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep dihydrochloride (300 mg/day) in normotensive patients (group A)
Number of subjects: 22
Study 11340355 — intervention group
Group type: COMPARATOR
Intervention: Placebo in normotensive patients (group B)
Number of subjects: 22
Study 11340355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep dihydrochloride (300 mg/day) in hypertensive patients (group C)
Number of subjects: 22
Study 11340355 — intervention group
Group type: COMPARATOR
Intervention: Placebo in hypertensive patients (group D)
Number of subjects: 22
Study 9526893 — intervention group
Group type: EXPERIMENTAL
Intervention: a.m. training
Number of subjects: 12
Study 9526893 — intervention group
Group type: EXPERIMENTAL
Intervention: p.m. training
Number of subjects: 12
Study 7758055 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours
Number of subjects: 88
Study 7758055 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg, given as intermittent intravenous infusions every 6 hours
Number of subjects: 88
Study 7758055 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 88
Study 7758055 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 88
Study 2100659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode Iontophoresis using Strontium Chloride Solution (9%)
Number of subjects: 60
Study 2100659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode Iontophoresis using Strontium Chloride gel (9%)
Number of subjects: 60
Study 2100659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathode Iontophoresis using Sodium Fluoride solution (2%)
Number of subjects: 60
Study 2100659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathode Iontophoresis using Sodium Fluoride gel (2%)
Number of subjects: 60
Study 2100659 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 60
Study 373108 — intervention group
Group type: EXPERIMENTAL
Intervention: Neophyllin (4 or 8 tablets, each containing 56 mg proxyphylline and 84 mg diprophylline)
Number of subjects: 16
Study 373108 — intervention group
Group type: EXPERIMENTAL
Intervention: Neophyllin (8 tablets) with prior inhalation of 0.5 mg salbutamol
Number of subjects: 16
Study 373108 — intervention group
Group type: COMPARATOR
Intervention: Neo-Biphyllin (4 slow release coated tablets, 75 mg teophylline each)
Number of subjects: 16
Study 373108 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (in Neophyllin)
Number of subjects: 16
Study 31713940 — intervention group
Group type: EXPERIMENTAL
Intervention: 5α-reductase inhibitors
Number of subjects: 2003
Study 31713940 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2003
Study 31713940 — intervention group
Group type: EXPERIMENTAL
Intervention: 5α-reductase inhibitors (at least 3 years use)
Number of subjects: 2003
Study 31713940 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (at least 3 years use)
Number of subjects: 2003
Study 31302234 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 32
Study 28156049 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS-TECH intervention group
Number of subjects: 78
Study 28156049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 26025794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib for 3 days followed by oral celecoxib for 4 days
Number of subjects: 90
Study 26025794 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2-specific inhibitors
Number of subjects: 90
Study 26025794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient postoperative analgesia
Number of subjects: 90
Study 23978944 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF priming
Number of subjects: 183
Study 23978944 — intervention group
Group type: COMPARATOR
Intervention: G-CSF post-chemotherapy
Number of subjects: 183
Study 23978944 — intervention group
Group type: EXPERIMENTAL
Intervention: Late consolidation with autologous stem cell transplantation
Number of subjects: 183
Study 23978944 — intervention group
Group type: COMPARATOR
Intervention: One consolidation cycle
Number of subjects: 183
Study 22491395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 80
Study 22491395 — intervention group
Group type: COMPARATOR
Intervention: Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT)
Number of subjects: 80
Study 19538744 — intervention group
Group type: EXPERIMENTAL
Intervention: Design effect formula for multicenter studies
Number of subjects: 0
Study 17207028 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg/day for 3 days)
Number of subjects: 930
Study 17207028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefcapene pivoxil hydrochloride (300 mg/day for 3 days)
Number of subjects: 930
Study 17207028 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 930
Study 15311830 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS ON
Number of subjects: 10
Study 15311830 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS OFF
Number of subjects: 10
Study 15311830 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched normal subjects)
Number of subjects: 10
Study 11806608 — intervention group
Group type: EXPERIMENTAL
Intervention: Less palatable beverage exposure
Number of subjects: 0
Study 11806608 — intervention group
Group type: COMPARATOR
Intervention: Neutral or palatable beverage exposure
Number of subjects: 0
Study 9730318 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 112
Study 9730318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 10074756 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray tube angulation of 5 degrees or less
Number of subjects: 8
Study 10074756 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray tube angulation of more than 5 degrees
Number of subjects: 8
Study 2636644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (0.4 g/kg body wt/day of protein and 0.1 g/kg body wt/day of essential amino acids)
Number of subjects: 57